Developing biomarkers for early detection of age related diseases
.svg){kind=small}
Welcome to Age Labs
.svg){kind=icon}
Age Labs is a Norwegian life science company that discovers, develops and commercializes diagnostic tests for the early detection of age-related diseases. Our pipeline includes a groundbreaking test for early detection of rheumatoid arthritis, a cutting-edge biological age predictor and a test predicting the severity of COVID-19 infection, as well as several other promising biomarkers, both for diagnostics and drug response prediction.
Services
Age Labs’ primary focus is on biomarker development for diagnostics. Leveraging our extensive track record and deep understanding in aging, genetics, and predictive analytics, we also offer comprehensive services, typically to customers in the pharmaceutical and nutraceutical industries. These services include custom biomarker development and comprehensive reports on epigenetic drug effects for use in clinical trials. We also deliver services to the health & wellness sector, including advanced biological age and disease risk measurements.
Biomarker Pipeline
By using advanced machine learning on epigenetic datasets from biobanks, we develop biomarkers for the early detection of diseases.
Our first diagnostic candidate is a test for the early diagnosis of rheumatoid arthritis.
We have several R&D projects in collaboration with pharma companies and public institutions in Norway.
For a quote
.svg){kind=icon}
© 2017-2023 Age Labs AS, reg.no 919.825.723.